Monoclonal antibody (mAb) therapy is proven to be effective at shortening symptom duration by an average of four days, and preventing severe illness, hospitalization, and death from COVID for ambulatory patients at high risk of progression to serious disease. In a survey of Coloradans, 96 percent of people surveyed said they would consider mAb treatment if a provider recommended it. Despite the proven effectiveness of mAb therapy, questions about efficacy, administration, access, talking to patients, and more prevent health care providers from maximizing the use of mAb treatment. This 90-minute webinar—a statewide collaboration led by the Colorado Department of Public Health & Environment—offers concise, actionable information followed by a live Q&A with clinical and implementation experts. 

The webinar will cover data around current mAb use in Colorado, a brief overview of how mAbs work and the use of mAbs in viral infections, clinical data supporting efficacy for use with COVID, clinical pathways/guidelines, essential logistics (infusion v. subQ, monitoring, adverse reactions, cost, insurance issues, how to communicate with patients), resources for further questions, and the webinar will end with an expert panel Q&A.